$DYAI Cashflow Statement | Understand Stock

$DYAI

$0.39 +$0.00 (0.31%) Close

$DYAI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Unrealized gain from investment in Alphazyme
Gain from the sale of investment in BDI
Gain on investment in BDI
Amortization of held-to-maturity securities, net
Amortization of debt issuance costs
Gain on investment in Alphazyme
Foreign currency exchange loss
Changes in operating assets and liabilities:
Interest receivable
Accounts receivable
Income tax receivable
Prepaid expenses and other current assets
Operating lease assets and liabilities, net
Accounts payable
Accrued expenses
Accrued interest
Nonrelated Party
Related Party
Deferred license revenue
Accrued interest
Accrued interest - related party
Deferred research and development obligations

Net cash used in operating activities
Cash flows from investing activities
Purchases of held-to-maturity investment securities
Proceeds from maturities of investment securities
Proceeds from the sale of investment in BDI
Proceeds from the sale of investment in Alphazyme
Net cash provided by (used in) investing activities

Cash flows from financing activities
Proceeds from issuance of convertible notes, net of issuance costs
Nonrelated Party
Related Party
Proceeds from public offering, net of offering costs
Proceeds from issuance of convertible notes, net of issuance costs
Proceeds from issuance of convertible notes, net of issuance costs - related party
Proceeds from exercise of options
Net cash provided by financing activities
Effect of exchange rate changes on cash
Net decrease in cash, cash equivalents and restricted cash
Cash and cash equivalents at beginning of period
Cash, cash equivalents and restricted cash at end of period
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Cash and cash equivalents
Restricted cash
Total cash, cash equivalents, and restricted cash
Supplemental cash flow information
Cash received from income tax refund
Vesting of restricted stock units
Conversion of convertible notes
Cash paid for interest
Right-of-use asset obtained in exchange for lease obligations

Supplemental noncash investing and financing information
Fair value of warrants issued in connection with the offering
Purchase and assignment of convertible note by related party

Comments